Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) receptor , is exhibiting promising data in initial patient studies. Ongoing inquiry https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/